Identification of a short sequence in the HCMV terminase pUL56 essential for interaction with pUL89 subunit

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Ligat, G ^a,b   Jacquet, C ^a,b   Chou, S ^c,d   Couvreux, A ^a   Alain, S ^a,b   Hantz, S ^a,b  

^a UMR 1092   (France)

^b LIMOGES UNIVERSITY HOSPITAL   (France)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BINDING; UL56 PROTEIN, CYTOMEGALOVIRUS; UL89 PROTEIN, CYTOMEGALOVIRUS; VIRAL PROTEIN;

AMINO ACID SEQUENCE; CELL LINE; CHEMISTRY; CONSERVED SEQUENCE; CYTOMEGALOVIRUS; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY; PROTEIN DOMAIN; PROTEIN SUBUNIT; VIRUS REPLICATION;

AMINO ACID SEQUENCE; CELL LINE; CONSERVED SEQUENCE; CYTOMEGALOVIRUS; HUMANS; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN SUBUNITS; VIRAL PROTEINS; VIRAL STRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 85027850693     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-09469-7     Document Type: Article

References (34)

1. Alain, S. et al. Detection of ganciclovir resistance after valacyclovir-prophylaxis in renal transplant recipients with active cytomegalovirus infection. J. Med. Virol. 73, 566-573 (2004).
2. Hantz, S. et al. Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. J. Antimicrob. Chemother. 65, 2628-2640 (2010).
3. Lischka, P. et al. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob. Agents Chemother. 54, 1290-1297 (2010).
4. Melendez, D. P. & Razonable, R. R. Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus. Infect. Drug Resist 8, 269-277 (2015).
5. Borst, E. M., Wagner, K., Binz, A., Sodeik, B. & Messerle, M. The essential human cytomegalovirus gene UL52 is required for cleavage-packaging of the viral genome. J. Virol. 82, 2065-2078 (2008).
6. Borst, E. M. et al. The human cytomegalovirus UL51 protein is essential for viral genome cleavage-packaging and interacts with the terminase subunits pUL56 and pUL89. J. Virol. 87, 1720-1732 (2013).
7. Borst, E. M. et al. The Essential Human Cytomegalovirus Proteins pUL77 and pUL93 are Structural Components Necessary for Viral Genome Encapsidation. J. Virol, doi:10.1128/JVI.00384-16 (2016).
8. Köppen-Rung, P., Dittmer, A. & Bogner, E. Intracellular distributions of capsid-associated pUL77 of HCMV and interactions with packaging proteins and pUL93. J. Virol, doi:10.1128/JVI.00351-16 (2016).
9. De Russy, B. M. & Tandon, R. Human cytomegalovirus pUL93 is required for viral genome cleavage and packaging. J. Virol. doi:10.1128/JVI.02382-15 (2015).
10. De Russy, B. M., Boland, M. T. & Tandon, R. Human Cytomegalovirus pUL93 Links Nucleocapsid Maturation and Nuclear Egress. J. Virol, doi:10.1128/JVI.00728-16 (2016).
11. Scholz, B., Rechter, S., Drach, J. C., Townsend, L. B. & Bogner, E. Identification of the ATP-binding site in the terminase subunit pUL56 of human cytomegalovirus. Nucleic Acids Res 31, 1426-1433 (2003).
12. Hwang, J.-S. & Bogner, E. ATPase activity of the terminase subunit pUL56 of human cytomegalovirus. J. Biol. Chem. 277, 6943-6948 (2002).
13. Thoma, C. et al. Identification of the interaction domain of the small terminase subunit pUL89 with the large subunit pUL56 of human cytomegalovirus. Biochemistry (Mosc.) 45, 8855-8863 (2006).
14. Couvreux, A. et al. Insight into the structure of the pUL89 C-terminal domain of the human cytomegalovirus terminase complex. Proteins 78, 1520-1530 (2010).
15. Nadal, M. et al. Structure and inhibition of herpesvirus DNA packaging terminase nuclease domain. Proc. Natl. Acad. Sci. USA 107, 16078-16083 (2010).
16. Eilers, M., Patel, A. B., Liu, W. & Smith, S. O. Comparison of helix interactions in membrane and soluble alpha-bundle proteins. Biophys. J. 82, 2720-2736 (2002).
17. Ansari, S. & Helms, V. Statistical analysis of predominantly transient protein-protein interfaces. Proteins 61, 344-355 (2005).
18. Scheffczik, H., Savva, C. G. W., Holzenburg, A., Kolesnikova, L. & Bogner, E. The terminase subunits pUL56 and pUL89 of human cytomegalovirus are DNA-metabolizing proteins with toroidal structure. Nucleic Acids Res 30, 1695-1703 (2002).
19. Bradley, A. J. et al. High-throughput sequence analysis of variants of human cytomegalovirus strains Towne and AD169. J. Gen. Virol. 90, 2375-2380 (2009).
20. Ullman, E. F. et al. Luminescent oxygen channeling immunoassay: measurement of particle binding kinetics by chemiluminescence. Proc. Natl. Acad. Sci. USA 91, 5426-5430 (1994).
21. Waller, H., Chatterji, U., Gallay, P., Parkinson, T. & Targett-Adams, P. The use of AlphaLISA technology to detect interaction between hepatitis C virus-encoded NS5A and cyclophilin A. J. Virol. Methods 165, 202-210 (2010).
22. Champier, G. et al. Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. Antivir. Ther. 13, 643-654 (2008).
23. Giesen, K., Radsak, K. & Bogner, E. The potential terminase subunit of human cytomegalovirus, pUL56, is translocated into the nucleus by its own nuclear localization signal and interacts with importin alpha. J. Gen. Virol 81, 2231-2244 (2000).
24. Buerger, I. et al. A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products. J. Virol. 75, 9077-9086 (2001).
25. Goldner, T. et al. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J. Virol. 85, 10884-10893 (2011).
26. Chou, S. Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. Antimicrob. Agents Chemother. 59, 6588-6593 (2015).
27. Walker, M. P., Yao, N. & Hong, Z. Promising candidates for the treatment of chronic hepatitis C. Expert Opin. Investig. Drugs 12, 1269-1280 (2003).
28. Chee, M. S. et al. Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169. Curr. Top. Microbiol. Immunol 154, 125-169 (1990).
29. Sievers, F. et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol. Syst. Biol. 7, 539 (2011).
30. McWilliam, H. et al. Analysis Tool Web Services from the EMBL-EBI. Nucleic Acids Res 41, W597-600 (2013).
31. Li, W. et al. The EMBL-EBI bioinformatics web and programmatic tools framework. Nucleic Acids Res 43, W580-584 (2015).
32. Kelley, L. A., Mezulis, S., Yates, C. M., Wass, M. N. & Sternberg, M. J. E. The Phyre2 web portal for protein modeling, prediction and analysis. Nat. Protoc. 10, 845-858 (2015).
33. Borst, E. M., Hahn, G., Koszinowski, U. H. & Messerle, M. Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants. J. Virol. 73, 8320-8329 (1999).
34. Hantz, S. et al. Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model. Antiviral Res. 98, 130-134 (2013).